Compare iShares MSCI ACWI ETF (ACWI) vs AstraZeneca plc (AZN) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
iShares MSCI ACWI ETF vs AstraZeneca plc — how do they compare? iShares MSCI ACWI ETF trades at $155.55, while AstraZeneca plc trades at $189.89 (market cap $294.08B). The key difference: AstraZeneca plc pays a 1.64% dividend while iShares MSCI ACWI ETF pays none, and iShares MSCI ACWI ETF is trading nearer its 52-week high, AstraZeneca plc nearer its low. Which is the better fit depends on your goals.
| ACWI | AZN | |
|---|---|---|
52-Week High | $159.97 | $209.48 |
52-Week Low | $128.32 | $137.44 |
Market Cap | — | $294.08B |
Sector | — | Health |
Enterprise Value | — | $320.32B |
Dividend Yield | — | 1.64% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACWI trades at $157.97, up 1.17% with a bullish technical signal from moving averages. The ETF shows strong institutional interest and positive news flow, with a dividend scheduled for June 2026. Key support lies at $156, while resistance is at $159.
Outlook remains positive due to robust EPS growth and investor inflows into global equity ETFs. Risks include overbought technical conditions and market volatility. The stock's valuation and momentum support a constructive view for long-term investors.
AstraZeneca (AZN) trades at $193.12, down 1.04% today, with a bullish technical signal supported by moving averages. The company reported strong 2025 results with revenue of $58.74B and net income of $10.23B, marking a 17.4% profit margin. Recent news highlights strategic collaborations and regulatory approvals for key drugs like Enhertu, reinforcing growth prospects.
AZN presents a favorable outlook with robust earnings growth and a solid pipeline, though valuation multiples like a P/E of 28.64 suggest premium pricing. Risks include competitive pressures and trial outcomes, but analyst consensus leans bullish with 47.5% buy ratings. Institutional interest remains high, supporting potential upside.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About iShares MSCI ACWI ETF
The fund generally will invest at least 80% of its assets in the component securities of its underlying index and in investments that have economic characteristics that are substantially identical to the component securities of its underlying index. The index is a free float-adjusted market capitalization index designed to measure the combined equity market performance of developed and emerging markets countries.
Read more on ACWI →About AstraZeneca plc
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across several major therapeutic classes, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, and immunology. The majority of sales come from international markets with the United States representing close to one third of its sales.
Read more on AZN →
